Benzinga | Sep 22, 2021 06:58AM EDT

Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta In Global Phase 2/3 SPECTRA Trial Dominated By Variants Of Concern And Interest

* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain)

* Primary and secondary efficacy endpoints were successfully met

* 100% efficacy against severe COVID-19 & hospitalization and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2 in SPECTRA

* 79% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant

* Favorable safety profile; no significant differences in systemic adverse events or severe/serious adverse events compared to placebo

* First COVID-19 vaccine to demonstrate significantly reduced risk of COVID-19 disease in previously infected individuals

* Additional SPECTRA results are available on Clover's corporate website